Malignant tumors of the small intestine are uncommon, accounting for less than 2% of digestive tract cancer. However, it is the first etiology for endocrine tumors, lymphomas or stromal tumors. They are characterized by anatomopathological heterogeneity and non-specific symptomatology. This causes a diagnostic delay and a fairly severe prognosis. This is a retrospective study that included patients with small intestine cancer who were treated in the Medical Oncology department from January 2015 to June 2019. The objective was to study the epidemiological, diagnostic and therapeutic and prognostic factors of small intestine cancer and to relate our experience in their therapeutic management. Forty-three cases were reported, with median age 58.2 years (37 to 86 years), with a male predominance (the sex ratio M/F of 1.3). 20,9 % of patients were diagnosed with complications such as acute occlusive syndrome or intestinal perforation. The tumor localization was 23.2% in the jejunum, 32.5% duodenal and 44.1% ileal. Histologically, adenocarcinoma was the most common type (51.2%) followed by neuroendocrine carcinoma (27.9% of cases) and stromal tumors (16.2% of cases). The majority of cases were diagnosed with advanced metastatic disease (55.8% of cases). The sites of metastasis were respectively the liver (30.4%), the lung (16.6%) bone and the peritoneum (8.3%). The treatment was surgical in 44.1% of cases and consisted of a segmental intestinal resection, followed by a terminally terminal anastomosis. Seventy-nine percent of patients were eligible for systemic treatment, of which 23.6% were in the adjuvant setting and 55.8% in palliative cases. The chemotherapy protocol depended on the histological type and was dominated by the 5FU-oxaliplatin combination in carcinomas, while the stromal tumors received TKI. After a median follow-up of 52.7 months, the median progression-free survival was 11.2 months and the median overall survival was 16.8 months all histological types combined. Malignant tumors of the small intestine pose diagnostic problems because of their scarcity and the absence of specific clinical signs. They are often operative discoveries in the event of an acute complication. The curative treatment is surgical resection regardless of the histological type. The prognosis remains reserved because of the late diagnosis of the tumor.